Show simple item record

dc.contributor.authorDu, Cheng
dc.contributor.authorJaggi, Meena
dc.contributor.authorZhang, Chuanyou
dc.contributor.authorBalaji, Kethandapatti
dc.date2022-08-11T08:09:39.000
dc.date.accessioned2022-08-23T16:38:42Z
dc.date.available2022-08-23T16:38:42Z
dc.date.issued2009-01-15
dc.date.submitted2010-03-26
dc.identifier.citationCancer Res. 2009 Feb 1;69(3):1117-24. Epub 2009 Jan 13. <a href="http://dx.doi.org/10.1158/0008-5472.CAN-07-6270">Link to article on publisher's site</a>
dc.identifier.issn0008-5472 (Linking)
dc.identifier.doi10.1158/0008-5472.CAN-07-6270
dc.identifier.pmid19141652
dc.identifier.urihttp://hdl.handle.net/20.500.14038/39306
dc.description.abstractbeta-Catenin is essential for E-cadherin-mediated cell adhesion in epithelial cells and also acts as a key cofactor for transcription activity. We previously showed that protein kinase D1 (PKD1), founding member of the PKD family of signal transduction proteins, is down-regulated in advanced prostate cancer and interacts with E-cadherin. This study provides evidence that PKD1 interacts with and phosphorylates beta-catenin at Thr(112) and Thr(120) residues in vitro and in vivo; mutation of Thr(112) and Thr(120) results in increased nuclear localization of beta-catenin and is associated with altered beta-catenin-mediated transcription activity. It is known that mutation of Thr(120) residue abolishes binding of beta-catenin to alpha-catenin, which links to cytoskeleton, suggesting that PKD1 phosphorylation of Thr(120) could be critical for cell-cell adhesion. Overexpression of PKD1 represses beta-catenin-mediated transcriptional activity and cell proliferation. Epistatic studies suggest that PKD1 and E-cadherin are within the same signaling pathway. Understanding the molecular basis of PKD1-beta-catenin interaction provides a novel strategy to target beta-catenin function in cells including prostate cancer.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=19141652&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1158/0008-5472.CAN-07-6270
dc.subjectAnimals
dc.subjectCadherins
dc.subjectCell Growth Processes
dc.subjectCell Movement
dc.subjectDown-Regulation
dc.subjectHumans
dc.subjectMice
dc.subjectNIH 3T3 Cells
dc.subjectPhosphorylation
dc.subjectProtein Kinase C
dc.subjectSubcellular Fractions
dc.subjectTRPP Cation Channels
dc.subjectTranscription, Genetic
dc.subjectbeta Catenin
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleProtein kinase D1-mediated phosphorylation and subcellular localization of beta-catenin
dc.typeJournal Article
dc.source.journaltitleCancer research
dc.source.volume69
dc.source.issue3
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/2105
dc.identifier.contextkey1246907
html.description.abstract<p>beta-Catenin is essential for E-cadherin-mediated cell adhesion in epithelial cells and also acts as a key cofactor for transcription activity. We previously showed that protein kinase D1 (PKD1), founding member of the PKD family of signal transduction proteins, is down-regulated in advanced prostate cancer and interacts with E-cadherin. This study provides evidence that PKD1 interacts with and phosphorylates beta-catenin at Thr(112) and Thr(120) residues in vitro and in vivo; mutation of Thr(112) and Thr(120) results in increased nuclear localization of beta-catenin and is associated with altered beta-catenin-mediated transcription activity. It is known that mutation of Thr(120) residue abolishes binding of beta-catenin to alpha-catenin, which links to cytoskeleton, suggesting that PKD1 phosphorylation of Thr(120) could be critical for cell-cell adhesion. Overexpression of PKD1 represses beta-catenin-mediated transcriptional activity and cell proliferation. Epistatic studies suggest that PKD1 and E-cadherin are within the same signaling pathway. Understanding the molecular basis of PKD1-beta-catenin interaction provides a novel strategy to target beta-catenin function in cells including prostate cancer.</p>
dc.identifier.submissionpathoapubs/2105
dc.contributor.departmentProgram in Molecular Medicine
dc.contributor.departmentDepartment of Urology
dc.contributor.departmentDepartment of Surgery
dc.source.pages1117-24


This item appears in the following Collection(s)

Show simple item record